Document:

exv4w1

 

Exhibit 4.1

AMENDED FOURTH SUPPLEMENTAL INDENTURE

between

SLM CORPORATION

and

DEUTSCHE BANK TRUST COMPANY AMERICAS

Dated as of December 17, 2004

 

 

     AMENDED FOURTH SUPPLEMENTAL INDENTURE, dated as of December 17, 2004 (this “Amended Fourth
Supplemental Indenture”), between SLM Corporation, a Delaware corporation (the
“Company”), and Deutsche Bank Trust Company Americas, as trustee (the “EdNotes
Trustee”), which amends the Fourth Supplemental Indenture, dated as of January 16, 2003 (the
“Supplemental Indenture”), between the Company and the EdNotes Trustee, as consented to by
JPMorgan Chase Bank (formerly known as The Chase Manhattan Bank) (the “Original Trustee”)
for the EdNotes (defined below) under the Indenture, dated as of October 1, 2000 (the “Base
Indenture”, together with this Amended Fourth Supplemental Indenture and the Supplemental
Indenture, each as amended or supplemented, collectively the “Indenture”), between the
Company (formerly known as USA Education, Inc.) and the Original Trustee.

RECITALS

     WHEREAS, the Company executed and delivered the Base Indenture to the Original Trustee to
provide for the future issuance of debentures, notes or other evidences of indebtedness of the
Company to be issued from time to time in one or more series as might be determined by the Company
under the Indenture, in an unlimited aggregate principal amount which may be authenticated and
delivered as provided in the Base Indenture;

     WHEREAS, pursuant to the terms of the Base Indenture, the Company established a series of
senior unsecured and unsubordinated notes known as the Medium Term Notes of the Company, Series B,
due nine months or longer from the date of issue, otherwise known as EdNotesSM (the
“EdNotes”) on January 23, 2003; the form and substance of the EdNotes and the terms,
provisions and conditions of the EdNotes are to be set forth in an officers’ certificate under
Section 2.02 of the Base Indenture;

     WHEREAS, pursuant to Rule 424(b) of the General Rules and Regulations under the Securities
Act, the Company (i) has filed with the Securities and Exchange Commission a Prospectus and a
Prospectus Supplement, each dated January 23, 2003, to Registration Statement (File No. 333-90316)
with respect to an offering of up to $2,000,000,000 of the EdNotes and (ii) will file with the
Securities and Exchange Commission a prospectus and a prospectus supplement to Registration
Statement (File No. 333-107132) with respect to an offering of up to $3,000,000,000 of the EdNotes;

     WHEREAS, the Company may file additional prospectuses and prospectus supplements to an
effective registration statement or registration statements with respect to additional offerings of
the EdNotes in the future;

     WHEREAS, the Company and the EdNotes Trustee hereby amend the Fourth Supplemental Indenture by
this Amended Fourth Supplemental Indenture; and

     WHEREAS, all requirements necessary to make this Amended Fourth Supplemental Indenture a valid
instrument in accordance with its terms have been performed, and the execution and delivery of this
Amended Fourth Supplemental Indenture have been duly authorized in all respects.

 

 

     NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which
hereby is acknowledged, the parties covenant and agree as follows:

     Article 4.1 is hereby replaced in its entirety by the following text:

ARTICLE 4

MISCELLANEOUS

     4.1 Notices.

     (a) Any notice or communication by the Company or the EdNotes Trustee is duly given if in
writing and delivered in person, sent by facsimile or mailed by certified mail:

     if to the Company to:

SLM Corporation

12061 Bluemont Way

Reston, Virginia 20190

Attention: Executive Vice President and Chief Executive Officer

Facsimile No.: 703-984-5673

     if to the EdNotes Trustee to:

Deutsche Bank Trust Company Americas

60 Wall Street, 27th Floor

New York, New York 10005

Attention: Trust & Securities Services

Facsimile No.: 212-797-8614

     (b) The Company or the EdNotes Trustee by notice to the others may designate additional or
different addresses for subsequent notices or communications.

[remainder of page left blank intentionally]

-2-

 

     IN WITNESS WHEREOF, the parties hereto have caused this Amended Fourth Supplemental Indenture
to be duly executed as of the day and year set forth above.

	 	 	 	 	 
	 	 	SLM CORPORATION
	 
	 	 	 	 
	

	 	By:
	 	/s/ John F. Remondi

	

	 	Name:

Title:
	 	John F. Remondi

Executive Vice President, Finance
	 
	 	 	 	 
	 	 	DEUTSCHE BANK TRUST
COMPANY AMERICAS, not in its individual capacity, but solely as the EdNotes Trustee
	 
	 	 	 	 
	

	 	By:
	 	/s/ Susan Johnson

	

	 	Name:

Title:
	 	Susan Johnson

Vice President
	 
	 	 	 	 
	 	 	DEUTSCHE BANK TRUST
COMPANY AMERICAS, not in its individual capacity, but solely as the EdNotes Trustee
	 
	 	 	 	 
	

	 	By:
	 	/s/ Wanda Camacho

	

	 	Name:

Title:
	 	Wanda Camacho

Vice Presidentexv10w1

 

EXHIBIT 10.1

EQUITY INCENTIVE PLAN

TERMS & CONDITIONS

	 	1.	 	Representations. This Option may not be exercised if the issuance of shares of
common stock of United Therapeutics Corporation (the “Company”) upon such exercise would
constitute a violation of any applicable Federal or State securities or other law or
regulation.
	 
	 	2.	 	Non-Transferability. This Option may not be transferred in any manner other
than by will or the laws of descent and distribution, and may be exercised during the
lifetime of the Awardee only by the Awardee, other than in the case of an Incentive Stock
Option pursuant to Section 11.5 of the Plan. If the Awardee dies prior to exercising a
vested Option, the Option may be exercised by the person or persons entitled to do so under
Section 7.2(c) of the Plan. The terms of this Option shall be binding upon the executors,
administrators, heirs, successors, and assigns of the Awardee.
	 
	 	3.	 	Vesting. For employees, this Option shall vest in accordance with the vesting
schedule so long as Awardee remains fully employed with the Company or its subsidiaries.
For members of the Board of Directors of United Therapeutics, this Option shall vest in
accordance with the vesting schedule so long as the Awardee serves as a member of the Board
of Directors of the Company for the period specified.
	 
	 	4.	 	Form of Payment. The exercise price shall be paid at exercise by payment in
lawful money of the United States of America in cash or by official bank or certified check
made payable to the Company or by such methods authorized by the Plan.
	 
	 	5.	 	Withholding. Pursuant to Section 14.3 of the Plan, the Company shall have the
authority to deduct, withhold or require the Awardee to remit such amounts necessary to
satisfy any governmental tax withholding requirements as a result of Awardee’s exercise of
this Option..
	 
	 	6.	 	Special Exercise Rights. Notwithstanding any other provision in the Plan or
this Agreement to the contrary, upon the Awardee’s death or Disability (as defined in the
Plan), this Option shall become fully exercisable. To the extent that this provision causes
this Option to exceed the dollar limitation set forth in Section 7.2(d), the excess Options
shall be deemed to be Non-Qualified Stock Options.
	 
	 	7.	 	Method of Exercise; Rights of Awardee in Stock.

	 	a.	 	Once vested, this Option may only be exercisable by an Awardee who is an
employee of the Company or its subsidiaries either (i) at any time that Awardee
remains fully employed with United Therapeutics or its subsidiaries, or (ii) for a
period of ninety (90) days following the date of termination of Awardee’s employment
with the Company or its subsidiaries. For members of the Board of Directors of
United Therapeutics, this Option shall be exercisable at any time prior to its
expiration.
	 
	 	b.	 	This Option shall be exercisable upon delivery to the Company of an
executed Option Exercise Form (a copy of which is attached hereto), accompanied by
payment in lawful money of the United States of America in cash or by official bank
or certified check made payable to the Company of the option exercise price as to
the shares being purchased or otherwise in accordance with the Plan. Neither the
Awardee nor his/her personal representatives, heirs, or legatees shall have any
rights or privileges of a shareholder of the Company with respect to the shares
issuable upon the exercise of this Option, unless and until certificate(s)
representing such shares shall have been issued and delivered in accordance with the
terms hereof. This Option shall lapse and without further force and effect if it
remains unexercised by the Awardee who is an employee of
the Company or its subsidiaries ninety (90) days following the date of termination of
Awardee’s employment with the Company or its subsidiaries.

The Awardee acknowledges receipt of a copy of the Plan, a copy of which is annexed hereto, and
represents that he/she is familiar with the terms and provisions thereof. The Awardee hereby
accepts this Option subject to all the terms and provisions of the Plan. The Awardee hereby agrees
to accept as binding, conclusive, and final all decisions and interpretations of the Board of
Directors and, where applicable, the Compensation Committee of the Board of Directors, upon any
questions arising under the Plan.exv10w2

 

EXHIBIT 10.2

EQUITY INCENTIVE PLAN

TERMS & CONDITIONS

NON-EMPLOYEES

	 	1.	 	Representations. This Option may not be exercised if the issuance of shares of
common stock of United Therapeutics Corporation (the “Company”) upon such exercise would
constitute a violation of any applicable Federal or State securities or other law or
regulation.
	 
	 	2.	 	Non-Transferability. This Option may not be transferred in any manner
otherwise than by will or the laws of descent and distribution, and may be exercised during
the lifetime of the Awardee only by the Awardee, other than in the case of an Incentive
Stock Option pursuant to Section 11.5 of the Plan. If the Awardee dies prior to exercising
a vested Option, the Option may be exercised by the person or persons entitled to do so
under Section 7.2(c) of the Plan. The terms of this Option shall be binding upon the
executors, administrators, heirs, successors, and assigns of the Awardee.
	 
	 	3.	 	Vesting. This Option shall vest in accordance with the vesting schedule so
long as Optionee performs the agreed-upon consulting services for the Company or its
subsidiaries for the period specified.
	 
	 	4.	 	Form of Payment. The exercise price shall be paid at exercise by payment in
lawful money of the United States of America in cash or by official bank or certified check
made payable to the Company or by such methods authorized by the Plan.
	 
	 	5.	 	Withholding. Pursuant to Section 14.3 of the Plan, the Company shall have the
authority to deduct, withhold or require the Awardee to remit such amounts to satisfy any
governmental tax withholding requirements. The form in which the applicable tax
requirements will be satisfied under this Agreement is that as a condition to the issuance
of shares of common stock of the Company under this Option, the Company will withhold in
accordance with applicable law from any cash compensation payable to Awardee any taxes
required to be withheld by the Company under Federal, State or Local law as a result of
Awardee’s exercise of this Option.
	 
	 	6.	 	Special Exercise Rights. Notwithstanding any other provision in the Plan or
this Agreement to the contrary, upon the Awardee’s death or Disability (as defined in the
Plan), this Option shall become fully exercisable. To the extent that this provision causes
this Option to exceed the dollar limitation set forth in Section 7.2(d), the excess Options
shall be deemed to be Non-Qualified Stock Options.
	 
	 	7.	 	Method of Exercise; Rights of Awardee in Stock. At any time prior to its
expiration this Option shall be exercisable upon delivery to the Company of an executed
Option Exercise Form (a copy of which is attached hereto), accompanied by payment in lawful
money of the United States of America in cash or by official bank or certified check made
payable to the Company of the option exercise price as to the shares being purchased or
otherwise in accordance with the Plan. Neither the Awardee nor his/her personal
representatives, heirs, or legatees shall have any rights or privileges of a shareholder of
the Company with respect to the shares issuable upon the exercise of this Option, unless
and until certificate(s) representing such shares shall have been issued and delivered in
accordance with the terms hereof.

The Awardee acknowledges receipt of a copy of the Plan, a copy of which is annexed hereto, and
represents that he/she is familiar with the terms and provisions thereof. The Awardee hereby
accepts this Option subject to all the terms and provisions of the Plan. The Awardee hereby agrees
to accept as binding, conclusive, and final all decisions and interpretations of the Board of
Directors and, where applicable, the Compensation Committee of the Board of Directors, upon any
questions arising under the Plan.

Enclosures:

United Therapeutics Corporation Amended and Restated Equity Incentive Plan

Option Exercise Form

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}]]